News - MET mutation - LARVOL VERI

23h

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (clinicaltrials.gov)

P1, N=19, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting

23 hours ago

Enrollment closed

MET (MET proto-oncogene, receptor tyrosine kinase)

MET exon 14 mutation • MET mutation

Keytruda (pembrolizumab) • Tepmetko (tepotinib)

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC (clinicaltrials.gov)

P2, N=19, Not yet recruiting, Shanghai Chest Hospital

2 days ago

New P2 trial

KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

KRAS G12C • MET amplification • ALK rearrangement • MET exon 14 mutation • MET overexpression • ROS1 rearrangement • MET mutation • KRAS G12 • ALK negative

vebreltinib (APL-101)

Firmonertinib for Adjuvant Therapy in Completely Resected Stage IA EGFR-Mutated NSCLC (ChiCTR2600121611)

P4, N=535, Recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital

3 days ago

New P4 trial • Real-world evidence

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • NRG1 (Neuregulin 1) • BRCA (Breast cancer early onset)

TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • ALK positive • RET fusion • ALK fusion • FGFR mutation • RET mutation • ROS1 fusion • MET mutation • RB1 mutation • NRG1 fusion • KRAS G12 • BRCA mutation

Ivesa (firmonertinib)

A prospective, randomized, double-arm, multi-center, phase II study to Investigate the Efficacy and Safety of Sintilimab in Combination with IpilimumabN01 and Chemotherapy in First-line Treatment of driver gene-negative advanced NSCLC with PDL1 TPS<1% (ChiCTR2600119741)

P2, N=80, PLA General Hospital; PLA General Hospital

3 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • HER-2 mutation • ALK mutation • ROS1 fusion • MET mutation

PD-L1 IHC 22C3 pharmDx

Yervoy (ipilimumab) • Tyvyt (sintilimab) • pemetrexed

Comparative Analysis of Molecular Profiles of Sporadic Odontogenic Keratocyst and Bilateral Odontogenic Keratocyst: A Next Generation Sequencing Study. (PubMed, Pediatr Dev Pathol)

The TP53 gene mutation plays a significant role in the pathogenesis of OKC and supports its neoplastic nature. Bilateral OKC showed additional NRAS mutation, and sporadic cases demonstrated MET and BRAF mutations.

4 days ago

Journal • Next-generation sequencing

BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog)

TP53 mutation • BRAF mutation • NRAS mutation • MET mutation

Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing. (PubMed, Nat Biotechnol)

We experimentally validated several actionable findings, including tepotinib to target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway in pancreatic cancer and gilteritinib to overcome MET mutation-driven drug resistance and metastasis. To facilitate exploration of our data, we provide KIRHub, a web-based tool that allows identification of existing inhibitors of wild-type and mutated kinases to guide precision oncology.

5 days ago

Journal

MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR (Fibroblast Growth Factor Receptor) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • MARK2 (Microtubule Affinity Regulating Kinase 2)

MET mutation

Xospata (gilteritinib) • Alunbrig (brigatinib) • Tepmetko (tepotinib)

Lung Cancer Driver Mutations in Middle Eastern Americans: Associations with Smoking and Comparative Analysis with Middle Eastern Populations. (PubMed, Avicenna J Med)

Understanding these dynamics is essential for developing targeted public health strategies that address the unique challenges faced by this population, balancing their cultural heritage with the realities of modern American life. Further analysis and wider scope studies are necessary to explore the implications of these findings on health outcomes.

5 days ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)

KRAS mutation • EGFR mutation • BRAF mutation • ALK positive • ALK mutation • MET mutation

TruSight Oncology 500 Assay • TruSight Tumor 15 Assay

CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer. (PubMed, J Clin Oncol)

Savolitinib plus durvalumab shows OS in MET-driven PRC, supporting the ongoing SAMETA RIII trial (ClinicalTrials.gov identifier: NCT05043090). ctDNA may be a useful predictive biomarker.

6 days ago

Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)

MET mutation

FoundationOne® CDx

Imfinzi (durvalumab) • Orpathys (savolitinib)

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study (clinicaltrials.gov)

P3, N=838, Active, not recruiting, SWOG Cancer Research Network | Trial primary completion date: Jan 2027 --> Nov 2025

8 days ago

Trial primary completion date

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF mutation • HER-2 mutation • MET mutation

Keytruda (pembrolizumab) • Cyramza (ramucirumab)

A multi-stage computational pipeline for repurposing FDA-approved drugs: application to EGFR C797S-mutant NSCLC. (PubMed, Front Chem)

Among the evaluated compounds, doripenem, norgestrel, oxymetholone, norethisterone, and ertapenem exhibited high docking scores and consistent interactions with crucial hinge-region residues, such as MET-793 and mutant SER-797, within the ATP-binding site. These findings suggest that ertapenem and oxymetholone are promising structurally unique scaffolds for targeting osimertinib-resistant EGFR C797S-driven NSCLC. While experimental validation is necessary, this study provides a computational framework for swift drug repurposing and lays a rational foundation for future biochemical evaluation and structure-guided optimization of next-generation EGFR inhibitors.

9 days ago

FDA event • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • MET mutation

Tagrisso (osimertinib)

10d

Clinicopathologic features of KRAS G12C-mutated non-small cell lung carcinomas:insights from 279 retrospective cases. (PubMed, Virchows Arch)

KRAS G12C-mutated NSCLC is clinically aggressive and frequently shows solid growth with rhabdoid, plasmacytoid, or SCC-like morphology, which may lead to misclassification and missed genetic testing. Immunohistochemistry and molecular profiling are essential for accurate classification and enabling targeted therapy.

10 days ago

Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR3 (Fibroblast growth factor receptor 3) • STK11 (Serine/threonine kinase 11) • NRG1 (Neuregulin 1) • TACC3 (Transforming acidic coiled-coil containing protein 3) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • NKX2-1 (NK2 Homeobox 1) • GNAS (GNAS Complex Locus) • TP63 (Tumor protein 63) • NAPSA (Napsin A Aspartic Peptidase)

PD-L1 expression • TP53 mutation • KRAS mutation • KRAS G12C • BRAF mutation • PIK3CA mutation • STK11 mutation • FGFR2 mutation • MET mutation • NRG1 fusion • KRAS G12

10d

NAPISTAR1-01: FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (clinicaltrials.gov)

P1/2, N=174, Recruiting, Tubulis GmbH | N=120 --> 174

10 days ago

Enrollment change • Platinum resistant • First-in-human

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FOLR1 ( Folate receptor alpha ) • SLC34A2 (Solute carrier family 34 member 2) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • MET exon 14 mutation • ALK mutation • RET mutation • ROS1 fusion • MET mutation • KRAS G12 • NTRK fusion